Research progress in myosin light chain 9 in malignant tumors.
10.11817/j.issn.1672-7347.2021.200814
- Author:
Yimeng YOU
1
,
2
,
3
;
Tingbo LIU
1
,
2
,
4
;
Jianzhen SHEN
1
,
2
,
5
Author Information
1. Fujian Institute of Hematology
2. Fujian Provincial Key Laboratory on Hematology
3. Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China. youyimengyym@163.com.
4. Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China.
5. Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China. doctorsjz@163.com.
- Publication Type:Journal Article
- Keywords:
malignant tumor;
molecular markers;
myosin light chain 9
- MeSH:
Biomarkers;
Humans;
Lung Neoplasms;
Male;
Myosin Light Chains/metabolism*;
Prognosis;
Prostatic Neoplasms
- From:
Journal of Central South University(Medical Sciences)
2021;46(10):1153-1158
- CountryChina
- Language:English
-
Abstract:
Myosin light chain 9 (MYL9) is a regulatory light chain of myosin, which plays an important role in various biological processes including cell contraction, proliferation and invasion. MYL9 expresses abnormally in several malignancies including lung cancer, breast cancer, prostate cancer, malignant melanoma and others, which is closely related to the poor prognosis, but the clinical significance for its expression varies with different types of cancer tissues. Further elucidating the molecular mechanism of MYL9 in various types of malignant tumor metastasis is of great significance for cancer prevention and treatment. At the same time, as a molecular marker and potential target, MYL9 may have great clinical value in the early diagnosis, prognosis prediction, and targeted treatment of malignant tumors.
